Summary
This 2016 multicentre study, published in Annals of Oncology, investigated the prevalence and spatial heterogeneity of FGFR3 mutations in invasive bladder cancer across a large international cohort. The research addresses a clinically relevant question about whether intratumoural FGFR3 mutation heterogeneity might influence the efficacy of perioperative anti-FGFR3 targeted treatments. The findings have implications for patient selection and treatment planning in bladder cancer oncology.
UK applicability
As a clinical oncology study on bladder cancer biology and targeted therapy, the findings would be directly applicable to UK cancer treatment pathways and NHS oncology practice, particularly in informing perioperative treatment strategies for invasive bladder cancer.
Key measures
FGFR3 mutation status and tumour heterogeneity; treatment response indicators as suggested by the study's focus on perioperative anti-FGFR3 therapy
Outcomes reported
The study examined the prevalence and heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations across tumour samples from patients with invasive bladder cancer. The research assessed implications for perioperative anti-FGFR3 targeted treatment strategies.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.